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S U M M A R Y
Objectives: Enterococcus faecalis is thought to possess a great deal of intrinsic resistance to several
antimicrobial agents. In this study we identiﬁed ampicillin- and erythromycin-resistant clinical isolates
of E. faecalis and sought to identify the resistance mechanisms among these isolates.
Methods: Twelve isolates of E. faecalis were collected from 12 different patients. Identiﬁcation of the
isolates and their susceptibility patterns were determined using the Phoenix automated phenotypic
identiﬁcation criteria. PCR ampliﬁcation and sequencing were used to detect b-lactamase production.
Colony blotting was performed in order to screen for multidrug efﬂux pump production. Extraction and
N-terminal sequencing of the multidrug efﬂux pumps was carried out.
Results: The E. faecalis isolates showed high resistance to erythromycin and ampicillin, with minimum
inhibitory concentrations of >16 mg/ml. PCR ampliﬁcation and sequencing showed that isolates
produced TEM-1 b-lactamase. Colony blotting showed that these isolates harbored multidrug efﬂux
pump genes. Multidrug efﬂux pump extraction, puriﬁcation, and sequencing showed the distribution of
mefA and msrA/msrB efﬂux pumps.
Conclusion: Two resistance mechanisms among E. faecalis are described – the production of TEM b-
lactamase and mefA and msrA/msrB efﬂux pumps. These results are of great interest because this is the
ﬁrst report of the co-existence of these resistance mechanisms among E. faecalis strains.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Enterococci are Gram-positive and facultative anaerobic bacteria
normally found in the human intestine.1 Over the past two decades,
enterococci have been identiﬁed with increasing frequency as
causative agents of nosocomial infections, paralleling the correlation
of antimicrobial resistance to most commonly used agents. As a
result, enterococci have emerged as one of the leading clinical
challenges for physicians when identiﬁed as the cause of serious or
life-threatening infections. Infections caused by bacteria of the
genus Enterococcus include urinary tract infections, nosocomial
bacteremia, intra-abdominal infections, and endocarditis.2
Bacterial resistance that contributes to shorter drug lifecycles is
achieved by four main mechanisms: (1) enzymatic inactivation,3§ This work was presented at the meeting of the Gordon Research Conference in
Multi-Drug Efﬂux Systems, ‘‘From molecular mechanisms to pharmacological
modulation’’, June 12–17, 2011, Les Diablerets, Switzerland.
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doi:10.1016/j.ijid.2011.09.024(2) modiﬁcation of the drug target(s), (3) reduction of intracellular
drug concentration by changes in membrane permeability4 and (4)
over-expression of efﬂux pumps.5 Further studies have shown that
a resistance mechanism by active drug efﬂux has become
increasingly important in the current threat of multidrug
resistance mechanisms. It involves certain bacterial transport
proteins that pump out toxic antimicrobial compounds from the
cell. Drug efﬂux pump proteins in bacteria fall into ﬁve distinct
protein superfamilies: ATP binding cassette (ABC) superfamily,
major facilitator superfamily (MFS), small multidrug resistance
(SMR) superfamily, multidrug and toxic compound extrusion
(MATE) superfamily, and resistance-nodulation-cell division
(RND) superfamily. These efﬂux pumps are mostly encoded by
chromosomal genes.4
Enterococci are intrinsically resistant to cephems,6 and most
enterococcal strains such as those of Enterococcus faecium and
Enterococcus avium, with the exception of Enterococcus faecalis,
are also resistant to penicillins and imipenem. However, there
are a few reports of penicillin- and imipenem-resistant E.
faecalis. Two mechanisms of b-lactam resistance in E. faecalis
have been reported: the production of b-lactamases that areses. Published by Elsevier Ltd. All rights reserved.
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penicillin-binding proteins (PBPs) that bind to antimicrobial
agents rendering them inactive. It has been reported that
modiﬁcation of the sequence of PBPs is the major cause of
resistance.8
The rapid emergence of antimicrobial resistance among the
enterococci has undoubtedly also contributed to their emergence
as prominent nosocomial pathogens, making them among the
most difﬁcult pathogens to treat.9 Unlike Gram-negative enteric
bacteria, the outer membrane does not protect the enterococcal
cell from attack by the antimicrobial agent. Lynch et al.
hypothesized that in the absence of an extracytoplasmic perme-
ability barrier, the most likely mechanism for intrinsic drug
resistance in enterococci may be active efﬂux.10
Erythromycin-resistant enterococci can be divided into two
phenotypic classes based on their pattern of cross-resistance to
other ‘macrolides, lincosamides and type B streptogramins’ (MLS).
Enterococci inducibly or constitutively resistant to all MLS
antibiotics possess erythromycin ribosomal methylase (erm)
genes, whereas strains inducibly resistant to only 14- and 15-
membered ring macrolides and type B streptogramins harbor
msrA, which encodes an ATP-dependent efﬂux pump.5
In this study, we report the ﬁrst occurrence of mefA (macrolide
efﬂux protein A) and msrA/msrB (methionine sulfoxide reductase
A/B) multidrug efﬂux pumps associated with the production of
TEM-1 b-lactamase among erythromycin- and ampicillin-resistant
clinical isolates of E. faecalis.
2. Materials and methods
2.1. Bacterial strains
A total of 12 isolates of E. faecalis were obtained from 12
different patients in Kasserine Hospital, Tunisia. Each isolate was
streaked onto LB agar supplemented with 4 mg/ml ampicillin.
Bacteriological media were obtained from Oxoid Ltd (Basingstoke,
UK). Bacterial species identity was conﬁrmed by the Phoenix
automated phenotypic identiﬁcation criteria (Becton Dickinson,
Oxford, UK).
2.2. Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) of selected antimi-
crobial agents were determined by broth microdilution. Custom-
designed microdilution trays containing dilutions of selected
antimicrobial agents in cation-adjusted Mueller–Hinton broth
(Diagnostic Pasteur, France) were inoculated, and results were
analyzed using the Clinical and Laboratory Standards Institute
(CLSI) guidelines.
2.3. Colony blotting experiments
Colony blotting was carried out by a slight modiﬁcation of the
procedure of Ivanov and Gigova.11 Isolates were grown on blood
agar plates (Oxoid Ltd) and incubated overnight at 37 8C; a
circular nylon membrane ﬁlter (Hybond-N+, Amersham Phar-
macia, UK) was then used to blot colonies by applying the
membranes to the surface of the agar for at least 1 min. The nylon
membrane ﬁlter was then transferred onto a Whatman 3MM
ﬁlter presoaked with 5% sodium dodecyl sulfate (SDS) and placed
colony side up for 5 min. The nylon ﬁlter was then carefully
detached, dabbed on Whatman 3MM paper to remove excess
moisture, and then placed onto Whatman 3MM paper presoaked
with denaturing solution (1.5 M NaCl in 0.5 M NaOH). After
5 min, the nylon ﬁlter was carefully removed, dabbed to dry on
Whatman 3MM paper, and carefully ﬂoated, colony side up, onneutralizing solution (0.65 M Tris–HCl, 1.5 M NaCl, pH 7.5). After
5 min, the ﬁlter was submerged in the neutralizing solution and
the cellular debris was carefully washed off the ﬁlter. The ﬁlter
was then placed on Whatman 3MM paper to remove excess
liquid. Finally, the ﬁlter was submerged in 6 SSC (saline-sodium
citrate) solution and again dabbed dry. The DNA was ﬁxed onto
the ﬁlter by incubation at 80 8C for at least 3 h.
2.4. Production of radio-labeled PCR products
PCR products derived from the TEM-1 and multidrug efﬂux
genes were generated from positive isolates (kindly provided by
Professor Timothy R. Walsh, Department of Infection, Immunity
and Biochemistry, School of Medicine, Cardiff University, UK).
Fifteen microliters of the PCR products were added to 8 ml of
DNase-free water and 10 ml of Random 9-mer Primers (Agilent
Technologies–Stratagene, Wilmington, USA) and then mixed in a
screw-top Eppendorf and boiled for 5 min. Five ml of 5 dCTP
(deoxycytidine triphosphate); 2.5 ml of 32P (Perkin Elmer,
Boston, USA) and 1 ml of Exo() Klenow (Agilent Technolo-
gies–Stratagene, Wilmington, USA) were then quickly added to
the mixture and deposed in a lead jar at 37 8C for 15 min. A new
column (NICK Columns Sephadex G-50 DNA Grade; illustra; GE
Healthcare, Buckinghamshire, UK) was used to purify the radio-
labeled PCR product. The mixture was deposited onto the
column, 320 ml of 0.1 M Tris–HCl buffer, pH 7.5 was added and
then moved to a collection tube, and then 430 ml of 0.1 M Tris–
HCl buffer was added and what ran through was collected. The
mixture was boiled for 6 min. At this stage the radio-labeled PCR
product was ready.
2.5. DNA hybridization
DNA hybridization was done by a modiﬁcation of the
procedure of Maniatis et al.12 The nylon ﬁlter was placed in a
hybridization cylinder tube (Hybaid, Middlesex, UK) and 20 ml of
prehybridization solution was added (6 SSC, 0.1% (w/v)
polyvinylpyrrolidone 400, 0.1% (w/v) Ficoll, 0.5% (w/v) SDS,
and 150 mg/ml denatured spermatozoid DNA). It was then
incubated in a Hybaid Maxi XL hybridization oven set at 65 8C for
5 h. The labeled probe prepared previously was denatured by
boiling for 5 min and then added to the container and incubated
at 65 8C overnight. After the hybridization step, the probe
solution was removed and the ﬁlter then washed, ﬁrst with
300 ml of 2 SSC containing 0.1% (w/v) SDS and then with 0.1
SSC containing 0.1% (w/v) SDS. These two washes were carried
out at 65 8C. After washing, the ﬁlter was removed, brieﬂy blotted
dry on Whatman 3MM paper, and wrapped in cling ﬁlm. A
HyperﬁlmTM (Amersham, GE Healthcare) was then guarded for
18 h at 80 8C. The spot was revealed using two baths of
developing and ﬁxing solutions.
2.6. PCR ampliﬁcation and sequencing of the blaTEM gene
The blaTEM resistance gene was detected by PCR ampliﬁcation.
Primers used for the blaTEM gene were TEM-D (5
0ATAAAATTCTT-
GAAGACGAAAG30) and TEM-R (50TTACCAATGCCTTAATCAGTGA30).
Bacterial DNA was prepared by suspending one loop of a fresh
colony in 500 ml of sterile distilled water and heating at 95 8C for
10 min. PCR ampliﬁcation of the blaTEM gene was carried out under
the following conditions: 95 8C for 5 min, followed by 35 cycles of
95 8C for 1 min, 60 8C for 1 min, 72 8C for 1 min, and 72 8C for
10 min. Sequencing was done with corresponding primers speciﬁc
for the blaTEM gene, in accordance with the method of Sanger et
al.13 An automated sequencer (377, ABI Prism, Perkin-Elmer, CT,
USA) was used.
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Multidrug efﬂux pump proteins were obtained from the cell
pellets by a modiﬁcation of the procedures of Kalmokoff et al.14
Cell pellets were suspended in 1 ml cell resuspension buffer
(50 mM NaP, pH 7.0, 300 mM NaCl, 2 mM MgCl2, 1 complete
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor
tablet, 0.2 mg/ml DNase I, pinch of lysozyme) and, though kept on
ice, sonicated (three bursts, 30 s each at an amplitude of 18 mm)
with a sonicator (SONIPREP 150). The unbroken cells and debris
were removed by centrifugation at 13 000 rpm for 4 min at 4 8C.
The supernatant ﬂuid was transferred to a 1.5-ml centrifuge tube,
and the cell membranes were separated from the supernatant by
centrifugation at 13 000 rpm for 45 min at 4 8C in a microcen-
trifuge (Eppendorf). The supernatant ﬂuid was decanted, and the
cell membrane pellets were carefully suspended in 0.2 ml of
10 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) buffer (pH 7.4). The cytoplasmic membranes were solubilized
by the addition of an equal volume of 10 mM HEPES (pH 7.4) and
cell resuspension buffer (50 mM NaP, pH 7.0, 300 mM NaCl, 2 mM
MgCl2, 1 complete EDTA-free protease inhibitor tablet, 0.2 mg/ml
DNase I, pinch of lysozyme) and incubated at room temperature for
60 min with intermittent shaking. The multidrug efﬂux pump
proteins were then sedimented by centrifugation at 13 000 rpm for
45 min at 4 8C. The supernatant ﬂuid was removed, and the
membrane pellets were then suspended in 80 ml of 10 mM HEPES
buffer and stored at 20 8C.
2.8. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE)
Forty microliters of multidrug efﬂux pump proteins preparation
was mixed with an equal volume of solubilization buffer (20%
glycerol, 10% 2-mercaptoethanol, 4% SDS in 0.125 M Tris (pH 6.8),
and 10 ml of 0.05% bromophenol blue per ml of buffer), and the
suspensions heated to 100 8C for 5 min and loaded onto an 11% SDS
polyacrylamide gel. Migration was performed for 1 h at 100 V and
then 3 h at 250 V. The gel containing the multidrug efﬂux pump
proteins preparation was stained by Coomassie blue method.15
2.9. Multidrug efﬂux pump puriﬁcation
The four protein bands were excised, and the proteins were
electro-eluted as described previously.16 The eluted protein was
concentrated in a Centricon-10 concentrator (Amicon, Inc.,
Beverly, MA, USA) and washed ﬁve times with H2O before being
recovered in a ﬁnal volume of 500 ml. Control of the purity of the
proteins was conﬁrmed by SDS-PAGE.Table 1
Antibiotic susceptibility of Enterococcus faecalis clinical isolates
Isolate MIC (mg/ml)
AMK AMP ATM CFZ CTX CAZ CXM C
E1 >8 >8 1 0.125 >8 >8 1 >
E2 >8 >8 4 0.125 >8 >8 0.5 >
E3 >8 >8 2 1 >8 >8 1 >
E4 >8 >8 2 0.125 >8 >8 0.125 >
E5 >8 >8 4 0.125 >8 >8 0.5 >
E6 >8 >8 8 0.5 >8 >8 0.5 >
E7 >8 >8 8 0.125 >8 >8 0.125 >
E8 >8 >8 8 0.5 >8 >8 0.5 >
E9 >8 >8 4 0.125 >8 >8 0.125 >
E10 >8 >8 1 1 >8 >8 0.5 >
E11 >8 >8 1 1 >8 >8 1 >
E12 >8 >8 4 1 >8 >8 0.125 >
AMK, amikacin; AMP, ampicillin; ATM, aztreonam; CFZ, cefazolin; CTX, cefotaxime; CAZ,
gentamicin; IMP, imipenem; MEM, meropenem; TZP, piperacillin–tazobactam; ERY, er2.10. Multidrug efﬂux pump protein sequencing
N-terminal amino acid sequencing of the multidrug efﬂux
pumps was carried out by modiﬁcation of the Matsudaira
procedure.17 Ten microliters of puriﬁed multidrug efﬂux pumps
in a ﬁnal volume of 400 ml was treated with 50 mM cyanogen
bromide (CNBr) in 70% (v/v) formic acid (in distilled water (dH2O))
at 25 8C for 24 h. Each sample was diluted 1:9 with dH2O,
lyophilized, and resuspended in 4 ml of dH2O before being
lyophilized again. This was repeated a second time, after which
the CNBr-treated protein was analyzed on an SDS-polyacrylamide
gel (15% (w/v) acrylamide in the running gel). The cathode running
buffer was supplemented with 1 mM thioglycolic acid in order to
reduce N-terminal blockage of the cleaved polypeptide fragments.
Following electrophoresis, the proteolytic fragments resolved by
SDS-PAGE were transferred onto an Immobilon-P membrane
(Millipore Corp., Bedford, MA, USA) at a constant current of 150 mA
and at 4 8C for 2.5 h.
The electroblotted protein was then stained with Coomassie
blue R250 (0.25% (w/v) in a solution of 45% (v/v) methanol and 10%
(v/v) acetic acid) for 1 min at room temperature and washed ﬁve
times for 5 min each with 100 ml of dH2O and 30 s with 50 ml of
methanol. The stained fragments were subsequently excised, and
N-terminal protein microsequencing (Edman degradation) was
carried out in a Hewlett Packard G1000A Automated Protein
Sequencer (Hewlett Packard, Minnesota, USA).
3. Results
3.1. Antibiotic susceptibility testing
All E. faecalis isolates were resistant to ampicillin and
erythromycin; they did not show MIC values for extended
spectrum b-lactamase (ESBL) production according to the CLSI
criteria. E. faecalis isolates showed high susceptibility to extended-
spectrum b-lactams and high resistance against erythromycin
(Table 1).
3.2. Colony blotting
Colony blotting and DNA hybridization using the TEM PCR
product as a radio-labeled probe showed that all isolates of E.
faecalis were positive for TEM. Probing of blotted isolates with
radio-labeled efﬂux gene demonstrated that E. faecalis isolates,
in addition to being positive for the TEM gene, were also positive
for multidrug efﬂux pumps gene (Figure 1). Two strains of
Klebsiella pneumoniae were used as positive and negative
controls.IP CS ETP GM IMP MEM TZP ERY TMP
8 >8 >8 >4 1 1 4/4 >16 0.5
8 >8 >8 >4 1 1 4/4 >16 1
8 >8 >8 1 1 1 4/4 >16 1
8 >8 >8 >4 1 1 4/4 >16 1
8 >8 >8 >4 1 1 4/4 >16 0.5
8 >8 >8 >4 1 1 4/4 >16 0.5
8 >8 >8 2 1 1 4/4 >16 0.125
8 >8 >8 >4 1 1 4/4 >16 0.125
8 >8 >8 >4 1 1 4/4 >16 1
8 >8 >8 2 1 1 4/4 >16 0.5
8 >8 >8 >4 1 1 4/4 >16 0.5
8 >8 >8 >4 1 1 4/4 >16 0.25
 ceftazidime; CXM, cefuroxime; CIP, ciproﬂoxacin; CS, colistin; ETP, ertapenem; GM,
ythromycin; TMP, trimethoprim.
Figure 1. Autorad after probing with (A) blaTEM-encoding gene and (B) multidrug efﬂux gene, in the 12 Enterococcus faecalis isolates (+ for positive control;  for negative
control).
Figure 2. PCR ampliﬁcation of blaTEM-1-encoding gene from Enterococcus faecalis
isolates on a 1% agarose gel. Lane 1: negative control; lanes 1–12: E. faecalis isolates;
lane M: marker.
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The results of ampliﬁcation of the TEM gene from E. faecalis
showed that all isolates harbored the blaTEM gene (Figure 2).
Puriﬁcation of the amplicons and sequencing results conﬁrmed
that TEM-1 b-lactamase was present in all blaTEM-positive isolates.
3.4. Erythromycin resistance and efﬂux activity
SDS-PAGE analysis of multidrug efﬂux pumps of E. faecalis
isolates revealed diverse multidrug efﬂux pump proﬁles among the
12 isolates (Figure 3). According to the multidrug efﬂux pumpFigure 3. Multidrug efﬂux pump protein proﬁles of Enterococcus faecalis clinical isolates
pump protein of E. faecalis isolates (E1 to E12).proﬁles, the isolates can be divided into two groups: the ﬁrst group
contains E1, E2, E5, E6, E7, E8, E9, E10, E11, and E12; they have the
same proﬁle, with overexpression of many multidrug efﬂux pumps
in several isolates like E1 and E6. The second group contains E3 and
E4; they have a different proﬁle to the other isolates, with an
overexpression of a multidrug efﬂux pump with a molecular
weight of 32 kDa in E3 compared to E4.
3.5. Protein sequencing and identiﬁcation of the efﬂux pumps
N-terminal amino acid sequencing of the efﬂux pumps was
undertaken, and the protein sequences obtained were submitted
to UniProt Knowledgebase, EMBL Outstation – European Bioinfor-
matics Institute. Protein alignment with database proteins (Figure
4) showed that the band with a molecular weight of 34 kDa has a
99% identity with Helicobacter msrA multidrug efﬂux pump; this
variant was present only in the ﬁrst group (E1, E2, E5, E6, E7, E8, E9,
E10, E11, and E12). The second band identiﬁed, referring to the
protein database, has a 98.5% identity with Streptococcus mefA
multidrug efﬂux pump; this variant of multidrug efﬂux pump was
present in all isolates, but in particular was found to be
overexpressed in E3 and E11. After many attempts, we were not
able to obtain the protein sequence of the two other bands with
molecular weights of 29 kDa and 31 kDa.
4. Discussion
We found ampicillin- and erythromycin-resistant isolates of
E. faecalis carrying blaTEM-1 b-lactamase and mefA and msrA/msrB on an 11% SDS polyacrylamide gel. Lane M: marker; lanes 1–12: multidrug efﬂux
Figure 4. Protein alignment of (A) sequence of Helicobacter msrA multidrug efﬂux pump vs. sequence of Enterococcus faecalis multidrug efﬂux pump, and (B) sequence of
Streptococcus mefA multidrug efﬂux pump vs. sequence of E. faecalis multidrug efﬂux pump.
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have been reported in enterococci, b-lactamase production is
one of these resistance mechanisms. Murray et al. have reported
b-lactamase-mediated penicillin resistance in E. faecalis.18
However, with the exception of a few reports, enterococci do
not normally produce b-lactamases.6 In contrast, penicillin- and
erythromycin-resistant E. faecalis isolates in this study produced
TEM-1 b-lactamase.
Detection of TEM-1 b-lactamase produced by E. faecalis isolates
is important because there are a few reports describing resistance
of these bacteria to b-lactams by b-lactamase production.
Therefore, b-lactamase has been shown to be encoded on
transferable plasmids in a number of E. faecalis strains, including
the original strain, HH22, from Texas.19 It is difﬁcult to directly
demonstrate the transfer of b-lactamase from one Enterococcus to
another. This is because a single bacterial cell, inoculated from
mating mixtures onto a penicillin-containing surface, does not
usually produce enough enzymes to survive on such surfaces. For
this reason, most conjugation studies with b-lactamase-positive
enterococci have been performed by selecting for transfer of
another resistance trait, and colonies resistant to this agent have
then been tested for penicillin resistance and b-lactamase
production.6
In contrast, efﬂux pumps are the major phenomena described in
E. faecalis strains, and the diversity of efﬂux pump families has
been described. The presence of 34 putative multidrug transpor-
ters in E. faecalis was suggested from genome sequencing
information.20 Among these, ABC transporters constitute the
majority (23 transporters; about 68% of the multidrug efﬂux
pumps). This probably suggests the physiological importance of
ABC efﬂux transporters in E. faecalis. E. faecalis shows fairly high
levels of resistance to many antimicrobial agents, presumably due
to the presence of many multidrug efﬂux pumps.20
In this study we found two different efﬂux pumps, mefA and
msrA/msrB; these efﬂux pumps are closely related to the major
MFS and ABC efﬂux pump families, respectively, and they confer
high resistance to erythromycin.
Physiological pumps conferring erythromycin resistance by
efﬂux have been described in several Gram-positive organisms,
such as the chloramphenicol resistance pump protein (cmr) efﬂux
pump from Corynebacterium glutamicum, which belongs to the MFS
class of pumps21; however this is not the case for Enterococcus.Nonetheless, acquired resistance to macrolides conferred by active
efﬂux has been detected recently in this species.20 The gene
responsible for efﬂux was initially called mefE and was subse-
quently assigned to the mefA gene class because of its close
relatedness to the mefA gene in Streptococcus pyogenes.22 The mefA
pump belongs to the MFS class. It contains 12 transmembrane
domains spanning the cytoplasmic membrane, and efﬂux is driven
by the proton motive force. mefA genes may be located on the
chromosomes (e.g., chromosomal chimeric tet(O)-mefA),23 but are
more often associated with transferable elements such as the
mefE-containing macrolide efﬂux genetic assembly (MEGA)
element or mefA-containing transposons.23 Another study sug-
gested that mefA and mefE genes were also observed in 9% of
erythromycin-resistant isolates of Streptococcus agalactiae, and
transformation was considered the main mechanism for resistance
gene acquisition.24 The mefA gene has also been found in Gram-
negative bacteria and can be transferred to E. faecalis and
Escherichia coli recipients.20
Despite its discovery in S. pyogenes and its worldwide
emergence in this species, the mefA gene is not conﬁned to
streptococci, but is being increasingly associated with a wide range
of Gram-positive and Gram-negative bacteria.25 In a few studies of
historical strains of pathogenic neisseriae, the mefA gene from a
1975 gonococcal isolate was found to Exhibit 100% amino acid
identity with the mefA gene from a pneumococcus isolated in the
1990s, suggesting that mefA elements occurred in non-streptococ-
cal populations for a long while before their identiﬁcation in
streptococci a few years ago.24
The second efﬂux pump identiﬁed in this study is the msrA/
msrB efﬂux pump. This type of efﬂux pump is known in Gram-
positive bacteria, particularly in enterococci, and it encodes for an
ABC transporter protein, which results in an energy-dependent
efﬂux of erythromycin.26 Previous studies have suggested that
msrA interacts with another protein, since it lacks the membrane-
spanning domains characteristic of ABC transporter pumps;
however, this putative protein has not been identiﬁed in
Staphylococcus aureus.27 While msrA and msrB efﬂux pumps lack
hydrophobic membrane-spanning domains of classical ABC
transporters and have considerable homology at the predicted
amino acid level, the question of whether they are functional
homologs remains unclear.28 mel another ABC transporter confers
an M phenotype in Streptococcus pneumoniae, while msrA confers
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mechanisms of these proteins. More recently, mel (designated
msrD) alone was found to be capable of conferring macrolide
resistance in a susceptible pneumococcal strain by transforma-
tion,29 but did not fully restore the MIC resistance of the donor
strain.
In summary, we found that only the involvement of the blaTEM
gene product confers penicillin-speciﬁc drug resistance. We also
conﬁrm and expand the reports of others showing that the mefA
efﬂux pump is found in North Africa, and rarely in Asia and North
and South America, while mefE is the predominant efﬂux
mechanism in North and South America, Europe, and Asia.30 The
mefA-containing strains in Europe appeared to be associated with
serotype 14, although they were isolated in different countries.
These isolates were also members of the same ribogroup,
suggesting that mefA is more likely to be clonal than mefE;
however, the small number of mefA isolates here does not allow a
deﬁnitive answer. In this study, we also veriﬁed the presence of an
msrA/msrB efﬂux pump in E. faecalis isolates from this same
collection, suggesting that other Gram-positive genera may also
carry this gene.
Protein accession numbers: The protein sequences obtained
were submitted to UniProt Knowledgebase, EMBL Outstation –
European Bioinformatics Institute: P86889 for macrolide-efﬂux
protein A (mefA) in Enterococcus faecalis; P86890 for peptide
methionine sulfoxide reductase msrA/msrB in Enterococcus faecalis.
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